Table 2.
(A) Multivariable clinical predictors for AF progression
| OR | 95% CI | P value | |
| Male sex | 1.8 | 0.87 to 3.51 | 0.116 |
| PR interval (per SD) | 1.5 | 1.14 to 2.06 | 0.004 |
| Impaired left atrial contractile function (per SD) | 1.8 | 1.16 to 2.69 | 0.008 |
| Moderate mitral valve regurgitation | 5.9 | 1.02 to 33.97 | 0.048 |
| Waist circumference (per SD) | 1.5 | 1.06 to 2.03 | 0.023 |
| (B) Multivariable predictors of AF progression including blood biomarkers | |||
| OR | 95% CI | P value | |
| Male sex | 3.5 | 1.65 to 7.41 | 0.001 |
| PR interval (per SD) | 1.6 | 1.21 to 2.21 | 0.002 |
| Impaired left atrial contractile function (per SD) | 1.7 | 1.05 to 2.70 | 0.031 |
| Factor XIIa:C1-esterase inhibitor (below median) | 2.7 | 1.26 to 5.56 | 0.01 |
| TFPI decrease (per SD) | 1.8 | 1.23 to 2.53 | 0.002 |
| NTproBNP (per SD) | 1.9 | 1.28 to 2.81 | 0.002 |
| PCSK9 (per SD) | 1.6 | 1.09 to 2.21 | 0.015 |
| PGLYRP1 (per SD) | 1.5 | 1.11 to 2.11 | 0.009 |
AF, atrial fibrillation; NTproBNP, N-terminal pro-brain natriuretic peptide; PCSK9, proprotein convertase subtilisin/kexin type 9; PGLYRP1, peptidoglycan recognition protein 1; TFPI, tissue factor pathway inhibitor.